Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1633
- Registration Number
- NCT03670810
- Locations
- 🇦🇹
KH der Barmherzigen Schwestern Linz BetriebsGesmbH, Linz, Oberösterreich, Austria
🇩🇪Praxis für Neurologie und Psychiatrie, Essen, North Rhine-Westphalia, Germany
🇨🇳Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
A Study of Two Formulations of LY3074828 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY3074828Device: Prefilled syringe (PFS)Device: Auto-injector (AI)
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT03662100
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 778
- Registration Number
- NCT03616964
- Locations
- 🇵🇱
Centrum Medyczne AMED, Warszawa, Poland
🇺🇸Joint and Muscle Medical Care, Charlotte, North Carolina, United States
🇺🇸Arthritis and Osteoporosis Associates of New Mexico, Las Cruces, New Mexico, United States
Study of LY3154207 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY3154207Drug: [14C]-LY3154207
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2018-11-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT03616795
- Locations
- 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States
Study to Compare 2 Formulations of LY900014 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY900014 U-100Drug: LY900014 U-200
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 69
- Registration Number
- NCT03616977
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 830
- Registration Number
- NCT03616912
- Locations
- 🇧🇪
CHU de Liège, Liège, Belgium
🇬🇷University General Hospital of Larissa, Larissa, Greece
🇭🇷Clinical Hospital Dubrava, Zagreb, Croatia
A Study of LY3316531 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY3316531Drug: Placebo
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT03611608
- Locations
- 🇧🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leuven, Belgium
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY3209590Drug: Placebo
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT03603704
- Locations
- 🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵Hakata Clinic, Fukuoka, Japan
🇯🇵P-one clinic, Hachioji, Tokyo, Japan
A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure)
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDrug: LY3322207
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 62
- Registration Number
- NCT03590860
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study of Lasmiditan in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 27
- Registration Number
- NCT03579940
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States